IndraLab

Statements

USP22 activates PI3K/Akt/mTOR. 5 / 5
| 5
reach
"32 , 33 , 34 To determine whether USP22 activates the PI3K/Akt/mTOR pathway via SIRT1‐mediated PTEN deacetylation, we used siRNA to silence the expression of SIRT1 in USP22‐overexpressing melanoma cells."
39135915
reach
"Moreover, PTEN inhibition could also reverse the USP22‐mediated activation of the PI3K/Akt/mTOR pathway (Figure 5K)."
39135915
reach
"These findings suggested that USP22 activates the PI3K/Akt/mTOR pathway and induces melanoma EMT via the SIRT1/PTEN axis.2.6 Drug screening identifies topotecan as a USP22-targeting molecule to suppress melanoma metastasis."
39135915
reach
"These results demonstrated that USP22 might promotes melanoma metastasis by inducing EMT activation.2.4 USP22 potentiates melanoma metastasis and EMT through activating PI3K/Akt/mTOR pathway."
39135915
reach
"These results suggested that USP22 potentiates melanoma metastasis and EMT through activating the PI3K/Akt/mTOR pathway.2.5 USP22 activates PI3K/Akt/mTOR pathway via SIRT1/PTEN axis."
39135915